SC12267

A board to discuss future MS therapies in early stage (Phase I or II) trials.

SC12267

Postby JFH » Mon Jun 05, 2006 2:06 am

Here's a drug from German company 4SC AG.
http://www.dvcg.de/gb/news/portfolio_presse.asp?artikel=504

Martinsried – 4SC AG, a drug discovery and development company specialising in research and development of therapeutic agents, announced today that they have successfully concluded Phase I studies for the small molecule product candidate SC12267 for treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. A safe and well tolerated dose was determined in these studies, which did not cause any relevant side effects after 14 days of once daily application of SC12267. Furthermore, the substance demonstrated a very good pharmacokinetic profile, suitable for once daily dosing.

I particularly like this bit :wink:
SC12267 is orally bio-available and demonstrates a half-life in man which allows a once daily dose in therapeutic use.
My emphasis.

But I cant locate any Phase II trial yet. Have mailled the co. I'll update if they reply.

{edit} This more recent (03/06) ref http://www.ziopharm.com/docs/RnD_Directions_March2006.pdf cites Serono Inc as the developer.
John
I am what I am
User avatar
JFH
Family Elder
 
Posts: 288
Joined: Sun Jul 11, 2004 2:00 pm
Location: England

Advertisement

Postby dignan » Mon Jun 05, 2006 7:46 am

Great find! I'm adding it to the pipeline, I guess phase I until you hear about a phase II trial.
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 2:00 pm


Return to Drug Pipeline

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service